Effects of Danlou tablet for the treatment of stable angina pectoris

Abstract

Introduction: Stable angina pectoris has a high prevalence and causes serious harm. Revascularization therapy can relieve angina pectoris to some extent, but it is not widely accepted in China due to the cost and secondary events. The Chinese proprietary medicine Danlou tablet has been widely used to treat angina pectoris, but previous trials had inadequate methodologies. In this study, we aim to conduct a randomized controlled trial to evaluate its efficacy and safety on stable angina. Methods and analysis: This study is a WeChat-based randomized, double-blind, and placebo-controlled clinical trial in China. Eligible participants are adults (aged 30–75 years) with CT-confirmed stable angina and traditional Chinese medicine-diagnosed intermingled phlegm and blood stasis syndrome. A total of 76 participants will be randomly allocated in a 1:1 ratio to the oral Danlou tablet group (1.5 mg a time, 3 times daily for 28 days) or the placebo group. Patients are permitted concomitant use of routine medications during these 28 days. The primary outcome is angina frequency per week. The secondary outcomes include angina severity, angina duration, traditional Chinese medicine efficacy, the withdrawal rate of emergency medications, blood lipids, and electrocardiograph efficacy. The WeChat app will be used to remind patients to take their medicines and fill out the forms. All data will be recorded in case report forms and analyzed by Statistical Analysis System software. Ethics and dissemination: This study has been approved by the Ethics Committee of Guang’anmen Hospital, China Academy of Chinese Medical Sciences in Beijing, China (No. 2019-225-KY). Trial registration number: ClinicalTrials.gov, ID: ChiCTR1900028068.

Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis

“…Danlou tablets are composed of Danshen ( Radix Salviae Miltiorrhiae ), Gualou ( Fructrs Trichosanthis ), Gegen ( Radix Puerariae ), Chishao ( Radix Paeoniae Rubra ), Xiebai ( Bulbus Allii Macrostemi ), Chuanxiong ( Rhizoma Chuanxiong ), Yujin ( Radix Curcumae ), Zexie ( Rhizoma Alismatis ), Huangqi ( Radix Astragali ), and Gusuibu ( Rhizoma Drynariae ), which has the effect of relieving chest, dispelling phlegm, dispersing knot, and activating blood to remove stasis. Therefore, it plays a good role in treating CHD of blood stasis and phlegm turbidimetry syndromes ( 41 ). Experimental studies have fully exemplified that Danlou tablets can reduce myocardial ischemia and reperfusion injury ( 42 ), regulate procholesterol efflux, and perform anti-inflammation by activating the PPAR α /ABCA1 signaling pathway; concurrently, the NF-κB signaling pathway is prevented, thereby playing its role in alleviating atherosclerosis ( 13 ).…”

Protective effects of paeoniflorin on cardiovascular diseases: A pharmacological and mechanistic overview

“…It has been widely used to treat coronary artery disease in China for a long time. Relevant clinical research demonstrated that DL can treat stable angina pectoris, alleviate adverse left ventricular remodeling after myocardial infarction, and reduce the peri-procedural myocardial injury among patients undergoing PCI for non-ST elevation acute coronary syndrome ( Wang et al, 2015 ; Mao et al, 2016 ; Yang et al, 2020 ; Zhao et al, 2021 ).…”

Danlou tablet inhibits high-glucose-induced cardiomyocyte apoptosis via the miR-34a-SIRT1 axis

“…Danlou tablet (Dan), a well-known compound preparation that contains 10 Chinese herbal medicines ( Trichosanthes kirilowii Maxim , Allium macrostemon Bunge , Radix Puerariae , Ligusticum chuanxiong hort , Salvia miltiorrhiza Bunge , Curcumae Radix , Astragalus propinquus Schischkin , Davallia mariesii Moore ex Bak , Alisma plantago-aquatica Linn , Paeoniae Radix Rubra ), is widely used to treat angina pectoris [ 16 ]. In the past decades, evidence has shown that Dan confers cardioprotective effects.…”